The combination of a celebrity ambassador with massive reach and a sharp upward revision in revenue guidance is a strong catalyst. Traders should watch for the Q3 2026 earnings report to confirm the Adjusted Free Cash Flow positivity trend and monitor IM8's daily serving run-rate for signs of sustained acceleration. The FY 2027 guidance of $400M+ implies a roughly 80% YoY growth rate from the FY 2026 midpoint, which is aggressive and will be a key focus for the market.
Price Chart
Executive Summary
Prenetics Global Ltd (PRE) announced a multi-year global partnership with actress Lily Collins as an IM8 Global Ambassador and shareholder, simultaneously raising FY 2026 revenue guidance to $220-230 million and initiating FY 2027 revenue guidance of $400+ million. The company also reported achieving positive consolidated Adjusted Free Cash Flow in July 2026. This filing bundles a high-profile brand ambassador deal with a significant upward revision in revenue guidance, signaling strong momentum for the IM8 supplement brand and a strategic expansion into the female consumer market.
Key Facts
- Prenetics raised FY 2026 revenue guidance to $220-230 million and initiated FY 2027 revenue guidance of $400+ million.
- The company achieved positive consolidated Adjusted Free Cash Flow in July 2026 and expects to remain positive for Q3 2026 and beyond.
- Lily Collins, with over 33 million social media followers and a ~5.9% engagement rate, joins IM8 as a Global Ambassador and shareholder.
- IM8 has delivered over 57 million servings since its December 2024 launch, currently ships 200,000 servings daily, and receives an order every 27 seconds.
- IM8 ships to 46 countries with 54% of revenue generated outside the US.
- IM8's annualized revenue run-rate reached approximately $251 million within 20 months of launch.
- New products include IM8 Hydration (Q4 2026) and a premium gummies line (H1 2027).
Financial Impact
FY 2026 revenue guidance raised to $220-230 million; FY 2027 revenue guidance initiated at $400+ million. IM8 annualized revenue run-rate ~$251 million. Positive Adjusted Free Cash Flow achieved in July 2026.
Risk Factors
- Revenue guidance is forward-looking and subject to execution risk; IM8 is a young brand and consumer demand may not sustain the implied growth trajectory.
- The company is pre-profitability on a GAAP basis; reliance on Adjusted Free Cash Flow as a non-IFRS metric may obscure underlying cash burn.
- Celebrity ambassador partnerships carry reputational risk and may not translate into proportional revenue growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (PRE) — Batch item 1 | 0001628280-26-058154 |
| Document: a6-kxlilycollinsannounceme.htm | 0001628280-26-058154 |
| Document: 0001628280-26-058154-index-headers.html | 0001628280-26-058154 |
| Document: 0001628280-26-058154-index.html | 0001628280-26-058154 |
| Document: 0001628280-26-058154.txt | 0001628280-26-058154 |
| 6-K Filing (PRE) — Batch item 6 | 0001628280-26-058154 |
| Document: a6-kxlilycollinsannounceme.htm | 0001628280-26-058154 |
| Document: 0001628280-26-058154-index-headers.html | 0001628280-26-058154 |
| Document: 0001628280-26-058154-index.html | 0001628280-26-058154 |
| Document: 0001628280-26-058154.txt | 0001628280-26-058154 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $21.27 | awaiting T+60 | — | $18.37 (−13.63%) |
Sep 22, 2026 4w ago | F-1/A | $22.90 | awaiting T+60 | — | $18.37 (−19.78%) |
Aug 26, 2026 8w ago | 6-K | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | Insider Cluster | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | 3 | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 20, 2026 9w ago | 6-K | $17.97 | awaiting T+60 | — | $18.37 (+2.23%) |
Aug 18, 2026 9w ago | 6-K | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 18, 2026 9w ago | Press Release | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 17, 2026 10w ago | 6-K | $19.37 | awaiting T+60 | — | $18.37 (−5.16%) |
Aug 7, 2026 11w ago | F-1/A | $18.26 | awaiting T+60 | — | $18.37 (+0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers